Skip to main content
Premium Trial:

Request an Annual Quote

RBM Achieves Milestone in Companion Diagnostic Project with Roche


Rules-Based Medicine, with its subsidiary Psynova Neurotech, said this week it has achieved a milestone in a companion diagnostic development program with Roche.

Using its DiscoveryMAP protein biomarker discovery platform as well as Psynova's biomarker database, the company identified a biomarker pattern useful in monitoring disease progression and predicting and monitoring the efficacy of a compound in Roche's central nervous system drug pipeline.

Based on the results, Roche has exercised its option to continue commercial development, which could result in additional future milestone and royalty payments to RBM and Psynova.

RBM was acquired last month by Myriad Genetics for $80 million (PM 04/28/2010). Upon announcing the purchase, Myriad director of investor relations and corporate communications Rebecca Chambers cited RBM's biomarker discovery services as a key asset, noting that, among other things, it establishes valuable relationships with pharmaceutical companies that use the platform for companion diagnostic discovery.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.